Category Archives: Emerging Markets
By Michael Christel | Published: April 4, 2014
In our second Q&A installment previewing next month’s iPharma2014 conference in New York City, we spoke with David Stern, executive VP of global commercial operations with OvaScience. Stern will be presenting on “Going Global – Innovative Tactics to Engage Emerging Markets and Extend the Global Strategy to a Regional Level.” Drawing from his time as […]
By Pharm Exec | Published: March 25, 2014
The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
By Pharm Exec | Published: March 21, 2014
Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.
By Pharm Exec | Published: March 7, 2014
The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital investments in biotechnology. According to research and consulting firm GlobalData, healthcare private equity investment in APAC increased by 125.8% between 2011 and 2013, whereas deal activities in Europe and North America decreased by 30.5% and 2.5% between 2012 […]
By Julian Upton | Published: February 26, 2014
Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.